Blood cancers, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 2
This trial looked at pembrolizumab and rituximab for Waldenstrom’s macroglobulinaemia (WM). It was for people whose WM had come back after treatment or treatment had stopped working.
The trial was open for people to join between 2019 and 2022. The team published the results in 2024.
Recruitment start: 6 September 2019
Recruitment end: 18 February 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Jaimal Kothari
CRUK & UCL Cancer Trials Centre
Merck, Sharp & Dohme LLC
University College London (UCL)
Last reviewed: 14 March 2025
CRUK internal database number: 15620
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
